Leonard Johnson - Search Results

Year	Number of Results
1999	1
2002	9
2003	10
2004	7
2005	8
2006	8
2007	9
2008	4
2009	10
2010	13
2011	16
2012	11
2013	5
2014	10
2015	6
2016	3
2017	2
2018	4
2019	8
2020	1
2021	6
2022	2
2023	8
2024	2

1

Conversion Discriminative Analysis on Mild Cognitive Impairment Using Multiple Cortical Features from MR Images.

Guo S, Lai C, Wu C, Cen G; Alzheimer's Disease Neuroimaging Initiative. Guo S, et al. Front Aging Neurosci. 2017 May 18;9:146. doi: 10.3389/fnagi.2017.00146. eCollection 2017. Front Aging Neurosci. 2017. PMID: 28572766 Free PMC article.

2

Ceftaroline-heteroresistant Staphylococcus aureus.

Saravolatz SN, Martin H, Pawlak J, Johnson LB, Saravolatz LD. Saravolatz SN, et al. Among authors: johnson lb. Antimicrob Agents Chemother. 2014 Jun;58(6):3133-6. doi: 10.1128/AAC.02685-13. Epub 2014 Mar 17. Antimicrob Agents Chemother. 2014. PMID: 24637680 Free PMC article.

3

Telavancin: a novel lipoglycopeptide.

Saravolatz LD, Stein GE, Johnson LB. Saravolatz LD, et al. Among authors: johnson lb. Clin Infect Dis. 2009 Dec 15;49(12):1908-14. doi: 10.1086/648438. Clin Infect Dis. 2009. PMID: 19911938 Review.

4

Biomarkers in the intensive care setting: A focus on using procalcitonin and C-reactive protein to optimize antimicrobial duration of therapy.

August BA, Kale-Pradhan PB, Giuliano C, Johnson LB. August BA, et al. Among authors: johnson lb. Pharmacotherapy. 2023 Sep;43(9):935-949. doi: 10.1002/phar.2834. Epub 2023 Jun 24. Pharmacotherapy. 2023. PMID: 37300522 Review.

5

Regulation of intestinal mucosal growth by amino acids.

Ray RM, Johnson LR. Ray RM, et al. Among authors: johnson lr. Amino Acids. 2014 Mar;46(3):565-73. doi: 10.1007/s00726-013-1565-2. Epub 2013 Aug 1. Amino Acids. 2014. PMID: 23904095 Free PMC article. Review.

6

Voriconazole: a new triazole antifungal agent.

Johnson LB, Kauffman CA. Johnson LB, et al. Clin Infect Dis. 2003 Mar 1;36(5):630-7. doi: 10.1086/367933. Epub 2003 Feb 10. Clin Infect Dis. 2003. PMID: 12594645 Review.

7

Lysophosphatidic acid type 2 receptor agonists in targeted drug development offer broad therapeutic potential.

Tigyi GJ, Johnson LR, Lee SC, Norman DD, Szabo E, Balogh A, Thompson K, Boler A, McCool WS. Tigyi GJ, et al. Among authors: johnson lr. J Lipid Res. 2019 Mar;60(3):464-474. doi: 10.1194/jlr.S091744. Epub 2019 Jan 28. J Lipid Res. 2019. PMID: 30692142 Free PMC article. Review.

8

The quad pill, a once-daily combination therapy for HIV infection.

Johnson LB, Saravolatz LD. Johnson LB, et al. Clin Infect Dis. 2014 Jan;58(1):93-8. doi: 10.1093/cid/cit637. Epub 2013 Sep 24. Clin Infect Dis. 2014. PMID: 24065329 Review.

9

Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus.

Saravolatz LD, Stein GE, Johnson LB. Saravolatz LD, et al. Among authors: johnson lb. Clin Infect Dis. 2011 May;52(9):1156-63. doi: 10.1093/cid/cir147. Clin Infect Dis. 2011. PMID: 21467022 Review.

10

Second-generation azole antifungal agents.

Kale P, Johnson LB. Kale P, et al. Among authors: johnson lb. Drugs Today (Barc). 2005 Feb;41(2):91-105. doi: 10.1358/dot.2005.41.2.882661. Drugs Today (Barc). 2005. PMID: 15821782 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

144 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

144 results

Results by year